Physician profile
Edward K Ko
NPI 1841364841
$58,405.94
in general payments reported to CMS, 2019-2025
50 companies · $3,113 in 2025
The $3,113 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $8,475 · 2021: $7,193 · 2022: $4,891 · 2023: $5,046 · 2024: $4,034 · 2025: $3,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $18.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,175.11 |
| Education | $18.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $25,592.81 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $4,960.61 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $3,159.91 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $2,602.13 | 2019-2025 | Livdelzi, Vemlidy |
| Novo Nordisk INC | $2,353.54 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,146.35 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Amgen INC. | $2,030.40 | 2019-2025 | Evenity, Tavneos, Prolia |
| Merck Sharp & Dohme LLC | $1,570.61 | 2019-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Lilly USA, LLC | $1,547.20 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,526.39 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,223.42 | 2021-2025 | |
| Abbvie INC. | $1,140.97 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $931.83 | 2019-2024 | Eliquis, Camzyos |
| Ironwood Pharmaceuticals, INC | $806.07 | 2019-2025 | Linzess |
| Paratek Pharmaceuticals, INC. | $800.00 | 2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.